Dennis Samuel, MD
Obstetrics & Gynecology · Bristol, TNNPI 1932102944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Astellas Pharma US Inc at 24.9% of the total.
Across 155 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$664
- AbbVie$484
- Sumitomo Pharma America, Inc.$234
- Exeltis, USA Inc.$178
- Sage Therapeutics, LLC$144
- Myovant Sciences Inc.$121
- plus $847 from 25 others
Across 50 payments — averaging $1690.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$82K
- Mitsubishi Tanabe Pharma Development America, Inc.$3K
What the payments were for
- Food & beverage$2,659100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 38 | $664 |
| AbbVie(2 entities) | 35 | $484 |
| Sumitomo Pharma America, Inc. | 11 | $234 |
| Exeltis, USA Inc. | 11 | $178 |
| Sage Therapeutics, LLC | 4 | $144 |
| Myovant Sciences Inc. | 6 | $121 |
| Pfizer | 8 | $113 |
| Boston Scientific | 3 | $77 |
| Therapeuticsmd, Inc. | 4 | $64 |
| Mayne Pharma Commercial LLC | 4 | $60 |
| Aspira Women's Health Inc | 1 | $58 |
| Avion Pharmaceuticals | 3 | $58 |
| Shield Therapeutics Inc | 3 | $52 |
| Duchesnay USA Incorporated | 4 | $46 |
| Hologic Sales And Service, LLC | 2 | $41 |
| Merck | 3 | $37 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Applied Medical Resources Corporation | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Organon | 1 | $19 |
| Intuitive Surgical | 1 | $17 |
| Bayer | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Coloplast | 1 | $16 |
| Coopersurgical, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Roche Diagnostics Corporation | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Minerva Surgical, Inc | 1 | $11 |
| Convatec Inc. | 1 | $11 |
| Amgen | 1 | $11 |
How this compares
$2,672 in reported general payments places this provider in the 70th percentile of 763 obstetrics & gynecology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 193 | $7,358 |
| OsphenaOspemifene | 14 | $4,839 |
| PremarinEstrogens, Conjugated | 15 | $4,039 |
| Oxybutynin Chloride ErOxybutynin Chloride | 68 | $1,471 |
| Terconazole | 25 | $766 |
| Ibandronate Sodium | 43 | $737 |
| Clobetasol Propionate | 18 | $736 |
| ProgesteroneProgesterone, Micronized | 21 | $714 |
| Medroxyprogesterone Acetate | 51 | $347 |
| Junel Fe 24Norethindrone-E.Estradiol-Iron | 13 | $186 |
| Triamcinolone Acetonide | 14 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Duchesnay USA IncorporatedOsphena | $46 | $4,83914 claims |
| PfizerPremarin | $113 | $4,03915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 763 obstetrics & gynecology providers in Tennessee.
Other obstetrics & gynecology in Bristol
- Ashley BlevinsBristol$15K
- Grover MayJohnson City$916K
- John GreenElizabethton$878K
- Brent LaingElizabethton$480K
- Larry FieldsKnoxville$323K
- Michael SwanNashville$146K
- Clarinda Burton-ShannonLebanon$114K
- Royce AdkinsNashville$95K
- Olga MuldoonNashville$91K
- Kimberly LooneyNashville$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.